32^nd International Conference on Insights in Ophthalmology May 02-03, 2023 London, UK

Jerry Katzman is the Company’s Chief Executive Officer, President, and Chairman of the Board of Directors. Dr. Katzman has always been an entrepreneur, scientist, and pioneer in medical science. His focus has targeted various biotechnology companies, biopharma, and Wall Street. Upon completion of his medical training, Dr. Katzman joined a multi-specialty group practice in Brandon, FL where he founded and established the group’s department of ophthalmology.

Ophthalmology, Optometery

Paul H Hughes is a renowned refractive surgeon in Australia gaining his BSc and MBBS from the University of NSW in Sydney, Australia. He introduced the early refractive procedures into Australia and was one of the first ophthalmologists to have his own private refractive suites, an ophthalmic centre of excellence (Southline eye centre). He has made the journey from Refractive Keratectomy (RK) through Automated Lamellar Keratoplasy (ALK) to Photorefractive Keratectomy (PRK) then to laser in situ keratomileusis (LASIK) with the excimer laser and is now using the femtosecond laser (Visumax) to perform 3rd generation refractive surgery Small incision lenticule extraction (SMILE).

Ophthalmology, Optometerist

Dr. Greiner, holder of three doctoral degrees, is an ophthalmologist, physician and surgeon, optometrist, teacher and medical research scientist, who has authored over 150 publications in the scientific and medical literature, and holds six U.S. patents and corresponding foreign patents in the areas of treatment of dry eyes and the integument (skin). With extensive training as both a basic and clinical scientist, many of these publications integrate both basic sciences and clinical medicine. In his 30 years of biomedical research, Dr. Greiner has presented more than 175 scientific papers at over 110 domestic and foreign meetings. Dr. Greiner is devoted to both scientific and clinical medical research as well as to clinical medicine in the fields of ophthalmology and surgery.

Ocular Surface, Ocular Diseases

Naj Sharif is a graduate of Southampton University, England (UK), where he received his BSc in Biochemistry and Physiology and his PhD in Neuroscience. He has been in the pharmaceutical industry for 31-years holding leadership positions of increasing scope and responsibility, spanning discovery research, drug development and regulatory affairs. His 22-year R&D tenure at Alcon resulted in his contributions to the discovery/development and US FDA and EMA approvals of Travatan® (Travoprost), Simbrinza®, Patanol® (Olopatadine) and Emedine® (Emedastine), to treat glaucoma/ocular hypertension and ocular allergies. He has also discovered, patented and out-licensed the first FP-prostaglandin-receptor antagonist (AL-8810) that is proving a useful pharmacological tool to dissect the role of FP-receptors in human and animal diseases.

Glaucoma, Ophthalmology Novel drugs

Ophthalmologist specialist Anterior Segment Surgeries Specialist. Hospital Santa Lucía. Buenos Aires.

Ophthalmology, optic Nerve